ProCE Banner Series

Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment

Join us for this case-based, interactive, CME-/CE-certified live webinar featuring expert perspectives on treatment for patients with nonmetastatic and advanced renal cell carcinoma. Be sure to bring your questions for the live Q&A session with the expert panel.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for oncologists, urologists, oncology nurses, oncology pharmacists, physician assistants/physician associates, and other healthcare professionals caring for patients with RCC.

All Events

Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment

Past Events

August

20

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

ProCE Banner Faculty
Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Topics

Genitourinary Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Renal Cell Carcinoma (RCC).

Target Audience
This program is intended for oncologists, urologists, oncology nurses, oncology pharmacists, physician assistants/physician associates, and other healthcare professionals caring for patients with RCC. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, considering current and emerging options, available clinical evidence, expert recommendations, and patient preferences
  • Plan evidence-based and expert recommended therapeutic sequencing strategies for patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved treatments for advanced RCC
  • Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-089-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

This activity is supported by educational grants from AVEO Pharmaceuticals, Inc. (“AVEO Oncology, an LG Chem company”) and Eisai. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.